Johnson & Johnson $JNJ Position Lessened by Flossbach Von Storch SE

Flossbach Von Storch SE reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,342,997 shares of the company’s stock after selling 145,995 shares during the quarter. Johnson & Johnson makes up 4.0% of Flossbach Von Storch SE’s holdings, making the stock its 7th largest position. Flossbach Von Storch SE’s holdings in Johnson & Johnson were worth $968,893,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson in the first quarter worth $48,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the first quarter worth $52,000. Finally, Pandora Wealth Inc. purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $65,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $186.50 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company’s 50 day moving average is $184.25 and its 200 day moving average is $168.70. The company has a market cap of $449.34 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several recent analyst reports. Sanford C. Bernstein upped their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Citigroup boosted their price target on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research report on Monday, October 20th. Finally, JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.